



## (51) International Patent Classification:

*A23L 33/135* (2016.01) *A61K 35/745* (2015.01)  
*A23L 33/21* (2016.01) *A61P 1/00* (2006.01)  
*A61K 31/702* (2006.01) *A61P 37/06* (2006.01)

## (21) International Application Number:

PCT/US2021/045951

## (22) International Filing Date:

13 August 2021 (13.08.2021)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

63/065,991 14 August 2020 (14.08.2020) US  
 63/225,170 23 July 2021 (23.07.2021) US

(71) Applicant: **PROLACTA BIOSCIENCE, INC.** [US/US];  
1800 Highland Avenue, Duarte, CA 91010 (US).

(72) Inventors: **BUTTON, Julie, E.**; c/o Prolacta Bioscience, Inc., 1800 Highland Avenue, Duarte, CA 91010 (US). **MCKENZIE, Gregory**; c/o Prolacta Bioscience, Inc., 1800 Highland Avenue, Duarte, CA 91010 (US). **ELSTER, Scott**; c/o Prolacta Bioscience, Inc., 1800 Highland Avenue, Duarte, CA 91010 (US). **REENS, Abigail**; c/o Prolacta Bioscience, Inc., 1800 Highland Avenue, Duarte, CA 91010 (US). **PIERCE, Jessica**; c/o Prolacta Bioscience, Inc., 1800 Highland Avenue, Duarte, CA 91010 (US).

(74) Agent: **VEITENHEIMER, Erich** et al.; Cooley LLP, 1299 Pennsylvania Ave., Suite 700, Washington, DC 20004 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

## (54) Title: HUMAN MILK OLIGOSACCHARIDE COMPOSITIONS FOR USE WITH BACTERIOTHERAPIES




FIG. 2C

(57) Abstract: Provided herein are methods and compositions for increasing the safety and effectiveness of a bacteriotherapy. In some aspects, a mixture of prebiotics, e.g., human milk oligosaccharides, are administered to a subject who has or will undergo a bacteriotherapy. In certain aspects, the mixture of prebiotics is administered in combination with a probiotic capable of internalizing and/or consuming the prebiotics. Also provided are methods for preparing or identifying strains of bacteria suitable for a bacteriotherapy, such as by incubating a mixture of bacteria obtained from stool in the presence of one or more of agents, e.g., human milk oligosaccharides, capable of promoting the growth of beneficial bacteria.

[Continued on next page]



**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*